Patients with relapsing remitting multiple sclerosis (RRMS) who received Sanofi Genzyme’s Lemtrada^® (alemtuzumab) experienced effects of treatment on disease activity that were maintained over seven years, according to data from the extension of two pivotal studies. These results will be presented this week during the 70^th annual meeting of the American Academy of Neurology (AAN) in Los Angeles, CA.

Sanofi today announced it will present nine abstracts at the American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 14-18. Building on its strong heritage in oncology, the company will share new, early-stage studies highlighting an emerging and dynamic portfolio that encompasses diverse strategies, including immuno-oncology (I-O).

The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for surgery. Advanced CCSC is the deadliest non-melanoma skin cancer. Cemiplimab is an investigational human monoclonal antibody targeting the checkpoint inhibitor PD-1 (programmed cell death protein-1).

Results from the Phase 1/2 trial (NEO1) and its ongoing extension study (NEO-EXT) show consistent safety data for Sanofi’s investigational avalglucosidase alfa (neoGAA) in patients with late-onset Pompe disease (LOPD) dosed over 3.5 years, without evidence of inhibition of enzyme activity over the analysis period. The study results were presented today at the 14th Annual WORLDSymposium 2018 in San Diego, California.